Shipping to Germany We Offer Worldwide Shipping
Login Wishlist

3-O-trans-p-Coumaroyltormentic acid

$830

  • Brand : BIOFRON

  • Catalogue Number : AV-B02413

  • Specification : 97%

  • CAS number : 121064-78-6

  • Formula : C39H54O7

  • Molecular Weight : 634.84

  • PUBCHEM ID : 14335955

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B02413

Analysis Method

HPLC,NMR,MS

Specification

97%

Storage

2-8°C

Molecular Weight

634.84

Appearance

Powder

Botanical Source

Structure Type

Triterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)OC(=O)C=CC6=CC=C(C=C6)O)O)C)C)C2C1(C)O)C)C(=O)O

Synonyms

(2α,3β)-2,19-Dihydroxy-3-{[(2E)-3-(4-hydroxyphenyl)-2-propenoyl]oxy}urs-12-en-28-oic acid/Urs-12-en-28-oic acid, 2,19-dihydroxy-3-[[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-, (2α,3β)-

IUPAC Name

(1R,2R,4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-1,11-dihydroxy-10-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid

Applications

Density

1.2±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

224.5±26.4 °C

Boiling Point

745.5±60.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C39H54O7/c1-23-16-19-39(33(43)44)21-20-36(5)26(31(39)38(23,7)45)13-14-29-35(4)22-27(41)32(34(2,3)28(35)17-18-37(29,36)6)46-30(42)15-10-24-8-11-25(40)12-9-24/h8-13,15,23,27-29,31-32,40-41,45H,14,16-22H2,1-7H3,(H,43,44)/b15-10+/t23-,27-,28+,29-,31-,32+,35+,36-,37-,38-,39+/m1/s1

InChl Key

BZORLJPADUHVJE-QWBBESJSSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:121064-78-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29590099

Abstract

Background
Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension, and cardiovascular events. Previous studies have suggested an increased risk of nonalcoholic fatty liver disease (NAFLD) in individuals with PCOS and implicated androgen excess as a potential driver.

Methods and findings
We carried out a retrospective longitudinal cohort study utilizing a large primary care database in the United Kingdom, evaluating NAFLD rates in 63,120 women with PCOS and 121,064 age-, body mass index (BMI)-, and location-matched control women registered from January 2000 to May 2016. In 2 independent cohorts, we also determined the rate of NAFLD in women with a measurement of serum testosterone (n = 71,061) and sex hormone-binding globulin (SHBG; n = 49,625). We used multivariate Cox models to estimate the hazard ratio (HR) for NAFLD and found that women with PCOS had an increased rate of NAFLD (HR = 2.23, 95% CI 1.86-2.66, p < 0.001), also after adjusting for BMI or dysglycemia. Serum testosterone >3.0 nmol/L was associated with an increase in NAFLD (HR = 2.30, 95% CI 1.16-4.53, p = 0.017 for 3-3.49 nmol/L and HR = 2.40, 95% CI 1.24-4.66, p = 0.009 for >3.5 nmol/L). Mirroring this finding, SHBG <30 nmol/L was associated with increased NAFLD hazard (HR = 4.75, 95% CI 2.44-9.25, p < 0.001 for 20-29.99 nmol/L and HR = 4.98, 95% CI 2.45-10.11, p < 0.001 for <20 nmol/L). Limitations of this study include its retrospective nature, absence of detailed information on criteria used to diagnosis PCOS and NAFLD, and absence of data on laboratory assays used to measure serum androgens. Conclusions We found that women with PCOS have an increased rate of NAFLD. In addition to increased BMI and dysglycemia, androgen excess contributes to the development of NAFLD in women with PCOS. In women with PCOS-related androgen excess, systematic NAFLD screening should be considered.

Title

Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database

Author

Balachandran Kumarendran, Conceptualization, Methodology, Data curation, Formal analysis, Software, Writing - original draft, Writing - review & editing,1,2,‡ Michael W. O’Reilly, Methodology, Data curation, Writing - original draft, Writing - review & editing,3,4,‡ Konstantinos N. Manolopoulos, Methodology, Data curation, Writing - original draft, Writing - review & editing,3,4,‡ Konstantinos A. Toulis, Data curation, Writing - review & editing,1 Krishna M. Gokhale, Data curation, Software, Writing - review & editing,1 Alice J. Sitch, Data curation, Formal analysis,1 Chandrika N. Wijeyaratne, Data curation, Supervision, Writing - review & editing,5 Arri Coomarasamy, Data curation, Supervision, Writing - review & editing,3,4 Wiebke Arlt, Conceptualization, Methodology, Data curation, Supervision, Writing - original draft, Writing - review & editing,#3,4,* and Krishnarajah Nirantharakumar, Conceptualization, Data curation, Formal analysis, Software, Methodology, Supervision, Writing - original draft#1,3,4,*

Publish date

2018 Mar

PMID

30190304

Abstract

Recently, the standardized reporting and data system for prostate-specific membrane antigen (PSMA)-targeted PET imaging studies, termed PSMA-RADS version 1.0, was introduced. We aimed to determine the interobserver agreement for applying PSMA-RADS to imaging interpretation of 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET examinations in a prospective setting mimicking the typical clinical workflow at a prostate cancer referral center. Methods: Four readers (2 experienced readers (ERs, >3 y of PSMA-targeted PET interpretation experience) and 2 inexperienced readers (IRs, <1 y of experience)), who had all read the initial publication on PSMA-RADS 1.0, assessed 50 18F-DCFPyL PET/CT studies independently. Per scan, a maximum of 5 target lesions was selected by the observers, and a PSMA-RADS score for every target lesion was recorded. No specific preexisting conditions were placed on the selection of the target lesions, although PSMA-RADS 1.0 suggests that readers focus on the most avid or largest lesions. An overall scan impression based on PSMA-RADS was indicated, and interobserver agreement rates on a target lesion-based, on an organ-based, and on an overall PSMA-RADS score-based level were computed. Results: The number of target lesions identified by each observer was as follows: ER 1, 123; ER 2, 134; IR 1, 123; and IR 2, 120. Among those selected target lesions, 125 were chosen by at least 2 individual observers (all 4 readers selected the same target lesion in 58 of 125 [46.4%] instances, 3 readers in 40 of 125 [32%], and 2 observers in 27 of 125 [21.6%]). The interobserver agreement for PSMA-RADS scoring among identical target lesions was good (intraclass correlation coefficient [ICC] for 4, 3, and 2 identical target lesions, ≥0.60, respectively). For lymph nodes, an excellent interobserver agreement was derived (ICC, 0.79). The interobserver agreement for an overall scan impression based on PSMA-RADS was also excellent (ICC, 0.84), with a significant difference for ER (ICC, 0.97) vs. IR (ICC, 0.74) (P = 0.005). Conclusion: PSMA-RADS demonstrated a high concordance rate in this study, even among readers with different levels of experience. This finding suggests that PSMA-RADS can be effectively used for communication with clinicians and can be implemented in the collection of data for large prospective trials.

KEYWORDS

18F-DCFPyL, PSMA-RADS, interreader, interobserver, PSMA, prostate cancer

Title

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging

Author

Rudolf A. Werner,1,2 Ralph A. Bundschuh,3 Lena Bundschuh,3 Mehrbod S. Javadi,1 Jeffrey P. Leal,1 Takahiro Higuchi,2,4 Kenneth J. Pienta,5 Andreas K. Buck,2 Martin G. Pomper,1 Michael A. Gorin,1,5 Constantin Lapa,*,2 and Steven P. Rowecorresponding author*,1,5

Publish date

2018 Dec

PMID

31636975

Abstract

Instances of crystal structures that remain isomorphous in spite of some minor changes in their respective mol­ecules, such as change in a substituent atom/group, can provide insights into the factors that govern crystal packing. In this context, an accurate description of the crystal structures of an isomorphous pair that differ from each other only by a chlorine-methyl substituent, viz. 5′′-(2-chloro­benzyl­idene)-4′-(2-chloro­phen­yl)-1′-methyl­dispiro­[acenaphthene-1,2′-pyrrolidine-3′,3′′-piperidine]-2,4′′-dione, C34H28Cl2N2O2, (I), and its analogue 1′-methyl-5′′-(2-methyl­benzyl­idene)-4′-(2-methyl­phen­yl)di­spiro­[acenaphthene-1,2′-pyrrolidine-3′,3′′-piperidine]-2,4′′-dione, C36H34N2O2, (II), is presented. While there are two C?H?O weak inter­molecular inter­actions present in both (I) and (II), the change of substituent from chlorine to methyl has given rise to an additional weak C?H?O inter­molecular inter­action that is relatively stronger than the other two. However, the presence of the stronger C?H?O inter­action in (II) has not disrupted the validity of the chloro-methyl exchange rule. Details of the crystal structures and Hirshfeld analyses of the two compounds are presented.

KEYWORDS

crystal structure, acenaphthene, supra­molecular, Hirshfeld surface, chlorine-methyl exchange

Title

Crystal structure and mol­ecular Hirshfeld surface analysis of acenaphthene derivatives obeying the chlorine-methyl exchange rule

Author

R. Sribala,a S. Indhumathi,b R.V. Krishnakumar,a and N. Srinivasana,*

Publish date

2019 Oct 1;